Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.

Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.
复制标题

叶酸强化早餐麦片可降低冠心病患者血浆同型半胱氨酸水平。

DOI:
--
复制
发表时间:
1998
影响因子:
158.5
通讯作者:
B. Upson
B. Upson
中科院分区:
医学1区
文献类型:
--
作者:
M. Malinow;P. Duell;D. Hess;P. H. Anderson;W. Kruger;B. Phillipson;R. Gluckman;P. Block;B. Upson

文献摘要

参考文献

被引文献

相似文献

背景
BACKGROUND The Food and Drug Administration (FDA) has recommended that cereal-grain products be fortified with folic acid to prevent congenital neural-tube defects. Since folic acid supplementation reduces levels of plasma homocyst(e)ine, or plasma total homocysteine, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid fortification might reduce plasma homocyst(e)ine levels. METHODS To test this hypothesis, we assessed the effects of breakfast cereals fortified with three levels of folic acid, and also containing the recommended dietary allowances of vitamins B6 and B12, in a randomized, double-blind, placebo-controlled, crossover trial in 75 men and women with coronary artery disease. RESULTS Plasma folic acid increased and plasma homocyst(e)ine decreased proportionately with the folic acid content of the breakfast cereal. Cereal providing 127 microg of folic acid daily, approximating the increased daily intake that may result from the FDA's enrichment policy, increased plasma folic acid by 31 percent (P=0.045) but decreased plasma homocyst(e)ine by only 3.7 percent (P= 0.24). However, cereals providing 499 and 665 microg of folic acid daily increased plasma folic acid by 64.8 percent (P<0.001) and 105.7 percent (P=0.001), respectively, and decreased plasma homocyst(e)ine by 11.0 percent (P<0.001) and 14.0 percent (P=0.001), respectively. CONCLUSIONS Cereal fortified with folic acid has the potential to increase plasma folic acid levels and reduce plasma homocyst(e)ine levels. Further clinical trials are required to determine whether folic acid fortification may prevent vascular disease. Until then, our results suggest that folic acid fortification at levels higher than that recommended by the FDA may be warranted.
DOI: 10.1001/jama.1996.03540230029031
发表时间: 1996
期刊: JAMA
影响因子: --
作者:
Tucker,KL;Mahnken,B;Wilson,PW;Jacques,P;Selhub,J
通讯作者: Selhub,J
DOI: 10.1016/0026-0495(94)90004-3
发表时间: 1994-12-01
影响因子: 9.8
作者:
STEEGERSTHEUNISSEN, RPM;BOERS, GHJ;ESKES, TKAB
通讯作者: ESKES, TKAB
DOI: 10.1161/01.cir.93.1.7
发表时间: 1996-01-01
期刊: CIRCULATION
影响因子: 37.8
作者:
Jacques, PF;Bostom, AG;Rozen, R
通讯作者: Rozen, R
DOI: 10.1161/01.cir.79.6.1180
发表时间: 1989-06-01
期刊: CIRCULATION
影响因子: 37.8
作者:
MALINOW, MR;KANG, SS;UPSON, B
通讯作者: UPSON, B